StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.52−4.33 (-3.44%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Kymera Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Kymera Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $429.98M, up 41.2% year over year. For fiscal 2025 it was $316.57M, up 31.8% from the year before. The highest annual figure on record is $316.57M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$316.57M+31.8%
FY2024Dec 31, 2024$240.25M+27.1%
FY2023Dec 31, 2023$189.08M+15.1%
FY2022Dec 31, 2022$164.25M+19.9%
FY2021Dec 31, 2021$137.02M+120.6%
FY2020Dec 31, 2020$62.11M+67.1%
FY2019Dec 31, 2019$37.16M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$128.51M+73.4%
Q2 FY2026Jun 30, 2026$119.48M+52.4%
Q1 FY2026Mar 31, 2026$98.16M+22.3%
Q4 FY2025Dec 31, 2025$83.83M+16.7%
Q3 FY2025Sep 30, 2025$74.09M+22.7%
Q2 FY2025Jun 30, 2025$78.39M+32.4%
Q1 FY2025Mar 31, 2025$80.26M+64.4%
Q4 FY2024Dec 31, 2024$71.82M+35.6%
Q3 FY2024Sep 30, 2024$60.41M+25.5%
Q2 FY2024Jun 30, 2024$59.20M+29.4%
Q1 FY2024Mar 31, 2024$48.82M+15.6%
Q4 FY2023Dec 31, 2023$52.97M+22.8%
Q3 FY2023Sep 30, 2023$48.12M+9.7%
Q2 FY2023Jun 30, 2023$45.77M+10.8%
Q1 FY2023Mar 31, 2023$42.23M+17.5%
Q4 FY2022Dec 31, 2022$43.13M+14.9%
Q3 FY2022Sep 30, 2022$43.88M+14.5%
Q2 FY2022Jun 30, 2022$41.29M+17.2%
Q1 FY2022Mar 31, 2022$35.94M+38.4%
Q4 FY2021Dec 31, 2021$37.53M+84.0%
Q3 FY2021Sep 30, 2021$38.31M+142.8%
Q2 FY2021Jun 30, 2021$35.22M+154.9%
Q1 FY2021Mar 31, 2021$25.96M+114.3%
Q4 FY2020Dec 31, 2020$20.39M+83.9%
Q3 FY2020Sep 30, 2020$15.78M+39.5%
Q2 FY2020Jun 30, 2020$13.82M–
Q1 FY2020Mar 31, 2020$12.12M–
Q4 FY2019Dec 31, 2019$11.09M–
Q3 FY2019Sep 30, 2019$11.31M–

More Kymera Therapeutics figures

See a number that looks wrong?